Company intelligence / Profile preview

ImmunoFlex

Vancouver, British Columbia, Canada

Ownership: Private
Employees: ~1
Development stage: Other

Overview

Completed exploratory clinical trial in 21 patients (aged 60-70) showing immune system changes via genomic analysis of T cell receptor CDR3 regions; beneficial changes observed in one group, supporting immunocompetence restoration; US and international patents submitted

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Chemistree Technology Inc. (investor)

Beyond the preview

Go deeper on ImmunoFlex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmunoFlex.

Explore the full profile